Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Background IMO-2055 is a Toll-like receptor 9 (TLR9) agonist that potentially enhances the efficacy of antitumor agents through immune stimulation. The objective of this phase Ib dose-escalation trial (3 + 3 design) was to determine the recommended phase II dose (RP2D) of IMO-2055 when combined with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2014-08, Vol.63 (8), p.787-796
Hauptverfasser:	Smith, David A., Conkling, Paul, Richards, Donald A., Nemunaitis, John J., Boyd, Thomas E., Mita, Alain C., de La Bourdonnaye, Guillaume, Wages, David, Bexon, Alice S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Cancer Research Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Dose-Response Relationship, Drug Epidermal growth factor Erlotinib Hydrochloride Humans Immunology Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medical research Medicine Medicine & Public Health Metastasis Middle Aged Neoplasm Metastasis Oligonucleotides - administration & dosage Oligonucleotides - adverse effects Oligonucleotides - pharmacokinetics Oncology Original Original Article Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Quinazolines - administration & dosage Quinazolines - pharmacokinetics Toll-Like Receptor 9 - agonists Toxicity Treatment Outcome Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!